AEterna Zentaris (AEterna Zentaris) Days Sales Outstanding

: 231.14 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

AEterna Zentaris's average Accounts Receivable for the three months ended in Dec. 2023 was $0.31 Mil. AEterna Zentaris's Revenue for the three months ended in Dec. 2023 was $0.12 Mil. Hence, AEterna Zentaris's Days Sales Outstanding for the three months ended in Dec. 2023 was 231.14.

The historical rank and industry rank for AEterna Zentaris's Days Sales Outstanding or its related term are showing as below:

AEZS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.1 Med: 69.23 Max: 34955.77
Current: 28.71

During the past 13 years, AEterna Zentaris's highest Days Sales Outstanding was 34955.77. The lowest was 1.10. And the median was 69.23.

AEZS's Days Sales Outstanding is ranked better than
86.71% of 888 companies
in the Biotechnology industry
Industry Median: 72.335 vs AEZS: 28.71

AEterna Zentaris's Days Sales Outstanding increased from Dec. 2022 (14.43) to Dec. 2023 (231.14).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

AEterna Zentaris Days Sales Outstanding Historical Data

The historical data trend for AEterna Zentaris's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

120.75

69.96

71.72

41.42

19.07

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																14.43	20.58	15.07	11,117.29	231.14

Competitive Comparison

For the Biotechnology subindustry, AEterna Zentaris's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Days Sales Outstanding falls into.

AEterna Zentaris Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

AEterna Zentaris's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.403	+	0.067)	/	2 )	/	4.498	*	365
=	0.235					/	4.498	*	365
=	19.07

AEterna Zentaris's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.546	+	0.067)	/	2 )	/	0.121	*	365 / 4
=	0.3065					/	0.121	*	365 / 4
=	231.14

AEterna Zentaris (NAS:AEZS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

AEterna Zentaris Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.